Healthcare System Reform & Innovative Medicine in China

Joseph Cho
RDPAC
2016 APAC, April 7th, 2016
Content

Healthcare reform and market trend
• Progress and Key issues
• Major Reform policies for pricing, reimbursement and bidding
• Pharma market trend

Regulatory reform for innovative medicines
• Document No. 44 by the state council
• Impact of Self inspection and audit of clinical trial data
• New Category for chemical drug registration
• Prioritized review for new drugs
• Ecosystem for drug innovation
China’s healthcare and pharmaceutical reform since 2009 implemented different pilots and tools

After multiple round mandatory price cuts in the past, hospital purchase price is believed to be the key cost control factor.

Before 2009, new drug approval, GMP, public hospital management policies were adjusted almost annually

**Pilots** were encouraged at regional level to explore better healthcare mechanism:
- 1993, hospital bidding
- 1998, urban employee reimbursement system (UEBMI)
- 2003, NRCMI
- ...

<table>
<thead>
<tr>
<th>Old healthcare reform</th>
<th>Start of new healthcare reform</th>
<th>2015</th>
</tr>
</thead>
<tbody>
<tr>
<td>2005</td>
<td>2009</td>
<td></td>
</tr>
<tr>
<td><strong>Drug reform</strong></td>
<td><strong>Start of new healthcare reform</strong></td>
<td>2015</td>
</tr>
<tr>
<td><strong>Medical service reform</strong></td>
<td><strong>Start of new healthcare reform</strong></td>
<td>2015</td>
</tr>
<tr>
<td>2009 Public hospital bidding</td>
<td>2013 County public hospital reform</td>
<td>2015 City public hospital reform</td>
</tr>
<tr>
<td><strong>Reimbursement</strong></td>
<td></td>
<td>2015</td>
</tr>
<tr>
<td>2009 More financial support, 90% coverage, OOP burden: 55%</td>
<td>2014 99% coverage, OOP burden: 33%</td>
<td>2015 Reimbursement payment standard, Critical Illness Insurance</td>
</tr>
</tbody>
</table>

Coverage increases, OOP burden lowered

**Planned Reimbursement standard** is supposed to control drug prices by reimbursement similar to German FRP system
Healthcare Reform

Healthcare Spending by Funding Source (CNY bln)

Source: MOH / NHFPC
Despite progress, significant hurdles remain that challenge the sustainability of the Chinese healthcare system.

### Key Challenges of China Healthcare System

#### High Patient Out-of-pocket Costs

**Patient OOP as % of Healthcare Expenditure in Global Markets (2013)**

- **CN**: 34%
- **IT**: 19%
- **CA**: 15%
- **JP**: 14%
- **DE**: 13%
- **US**: 12%
- **UK**: 9%
- **FR**: 8%

#### Growing Diverse Clinical Unmet Needs

**Disease Burden in China vs. Global Markets (Age-standardized DALYs per 10^5, 2010)**

- **Cardiovascular disease**: 2,038 (China) vs. 1,455 (Average of Neighboring Markets)
- **Cancer**: 2,847 (China) vs. 3,580 (Average of Neighboring Markets)
- **Infectious disease**: 1,455 (China) vs. 2,844 (Average of Neighboring Markets)

#### Far Behind in Fostering Innovation

**Biopharma R&D Investment in 2012 (Bn RMB)**

- **US**: 7,397
- **Europe**: 5,065
- **Japan**: 2,300
- **China**: 515

**Median time for new active substances approved in emerging markets (2007-2011, calendar days)**

- **CN**: 324
- **SK**: 324
- **IN**: 305
- **MX**: 335
- **BR**: 347

China Healthcare reform: Major policy changes for pricing, reimbursement and drug procurement in 2015

**Pricing**
1. Revision of <Price Law>
2. Promotion of competition policy and market-driving pricing mechanism;
3. Price monitoring & inspections?
4. Anti-trust issues.

**Reimbursement**
1. Guidelines on reimbursement standard;
2. Reimbursement standard pilots;
3. Reimbursement standards & budget management;
4. An integration of 3 medical insurances;
5. Commercial health insurance for catastrophic diseases.

**Procurement**
1. Price negotiation for patent drugs;
2. Classification of procurement, “double-envelope” tendering;
3. Price renegotiation;
4. Hospital zero markup;
5. Ratio limitation on drug usage.

---

**Quality Consistency Assessment for Generic Drugs**

---

**Pricing Reform for Pharmaceuticals**

---

**Quality Difference**

---

**CFDA Approval**

---

**Patient Access**

---

**RDPAC**
The Chinese Pharmaceutical Market trend
Chinese Hospital Market Growth 2007-2015

Source: IMS  Note: Hospital market with over 100 beds

- MAT growth for Q3 of 2015 dropped to 4.9%. IMS projects 9% CAGR for Chinese hospital market 2015-2019
- IMS projects the market share of county level hospitals to rise from 26% in MAT 10/2015 to 40% in 2020. Market shares of MNCs and domestics on county level market are 86% and 14% in MAT 10/2015. Such sales account for 29% and 15% of domestic and MNC hospital drug sales.
Highlights of Regulatory changes since 2015

### Directional & Positive
1. Resolve backlog
2. Improve drug quality
3. Encourage innovation
4. Optimized/streamlined regulatory procedures
5. Pilot MAH

### Still Remained Challenges:
- New Drug Definition and Chemical Drugs registration Classification
- Lack of tangible implementing and systematical coordination
- Need CFDA clarity the key uncertain areas

---

May 27, 2015
- New Registration Fee Standards for Drugs and Medical Devices

Jun, 2015
- Publication of 2015 China Pharmacopeia

Jul 22, 2015
- CFDA announcement on Clinical Trial self-inspection and verification

Aug 18, 2015
- The State Council opinions on drug review and approval system reforming (Doc. No. 44)

Nov 11, 2015
- CFDA certain policies for drug registration review and approval (No. 230)

Dec 01, 2015
- CFDA announcement on chemical drugs BE filing

Feb 25, 2016 & Beyond
- CFDA opinions on priority review and approval to resolve the backlog of registration (Doc. No. 19)
- CFDA announce of chemical drug registration category reform (Doc. No. 51)
- Upcoming DAL and DRR revision
RDPAC Assessment on No. 44 Document

Opinions of the State Council on Reforming the Review and Approval System for Drugs and Medical Devices (State Council Document 2015 No.44 ) on Aug 18

In General

This document is the directional guidance for CFDA Regulatory reform. Given the high profile announcement from the State Council, the CFDA is mandated to implement and ensure success of the reform. It is very positive for China Bio-pharma Industry development in overall. The implementation regulations need to be in place subsequently.
Key Positive Areas

1. **Resolve the backlog** of registration applications, try to clear the backlog inventory before the end of 2016 and achieve the timeline required in the upcoming DRR revision by 2018.

2. **Improve the quality of generic drugs.** Evaluation and approval of generics will be based on reference listed drugs (originators) as reference preparations to ensure consistent quality and efficacy of newly approved generic drugs in comparison with reference list drugs. By end of 2018, try to complete the quality consistent evaluation between oral preparations and reference preparations of national essential drugs.

3. **Encourage Biopharm innovation** oriented towards clinical value and accelerate the evaluation and approval of innovative drugs (the scope is listed), encourage China to have **Global Simultaneous Development** for new drug development and participate MRCT including the early development (Phase I&II). MRCT data can support NDA approval in China.

4. **Optimize/ streamline the evaluation and approval procedures** and accelerate approval for innovative drugs for urgent clinical needs. Increase CFDA/CDE's review and evaluation transparency.

5. **Carry out the pilot programs of MAH** for new drugs for the next three years.
Highlighted Issues

1. **New Drug Definition**: The drugs not yet marketed for distribution both within and outside the territories of PRC, is contradictory with International norms in Regulatory and IPR perspectives and could be a potential big risk for MNCs if NDA submission or approval is the cutting off date to be defined as New Drug category.

2. The selling prices for new products in China are required not higher than the prices in countries of origin or neighboring comparable markets of China. CFDA needs to clarify the objective of requirement and to define “the selling prices”.

3. **Methodology of quality consistent evaluation for Generics** need to defined clearly by CFDA, guideline announced for comments now.

4. “Licenses could be revoked if products haven't been marketed”. At renewal of license. This need CFDA to clarify further.

5. Since this document is directional guidance, so a set of implementation regulations are expected in near future. Also, in accordance with rule of by law, the reform measures in this document should be put into the upcoming DRR revision and DAL revision to ensure appropriate implementation.
CFDA Roadmap for Implementation of No. 44 Document of the state council

- No. 117 & No. 140 from CFDA
- No. 44 from SC
- Pilot MAH and Drug Registration Category Reform approved by NPC LC (Nov 4th, 2015)

Jul Aug Sep Oct Nov Dec Jan 2015 2016

A set of implementing regulations released

- BE filing System for Chemical Drugs Registration
- Tech. Requirement for Registration
- Accelerating Evaluation & Approval of Innovative Drugs
- Priority Reviewing to Solve Backlog
- Chemical Drugs Registration Category

A set of draft regulations or guidelines for commenting

- Draft Tech. Requirement for Registration
- Draft CDE working procedure for technical communication, reevaluation
- Draft Clinical Trials inspection procedure
- .....
**Inspection on clinical trials data:** CFDA clean up the NDA/BLA with the *frauds* and *integrity* issues, ~85% was withdrawn by the applicants.
New Regulatory Regulations Formally Published in 1Q 2016

- **Feb 6**
  • The State Council opinion on implementing generic quality and efficacy consistency evaluation

- **Feb 20**
  • CFDA notice to suspend E-coding implementation and seek comments on GSP revision

- **Feb 26**
  • CFDA opinions on implementing priority review and approval to resolve the backlog of drug registration applications

- **Mar 4**
  • CFDA announced of chemical drug registration category reform

- **Mar 11**
  • State Council document No. 11 on Promoting Pharmaceutical Industry Sound Development - **Top-level design**

**Positive**
- Encourage Innovation
- Improve drug quality
- Resolve backlog
- Insist on “Four Strictest”

**Still Remained Challenges:**
- Cat. 5 without Monitoring period doesn’t belong to “New Drug”
- Lack of tangible implementing and systematical coordination
- Need CFDA clarity the key uncertain areas
## Assessment of Chemical Drug Registration Category

<table>
<thead>
<tr>
<th>Registration Category</th>
<th>Category Description</th>
<th>Monitoring Periods</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>New drugs</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>1</td>
<td>Innovative drugs not marketed at home and abroad</td>
<td>5 years</td>
</tr>
<tr>
<td>2</td>
<td>New improved drugs that are not marketed at home and abroad</td>
<td>3-4 years</td>
</tr>
<tr>
<td><strong>Generics</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>3</td>
<td>Imitation of original drugs* that are marketed overseas but unavailable domestically</td>
<td>NA</td>
</tr>
<tr>
<td>4</td>
<td>Imitation of original drugs* that are marketed domestically</td>
<td>NA</td>
</tr>
<tr>
<td><strong>Imported drugs</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>5.1</td>
<td>Application for the domestic marketing authorization of original drugs (both API and DP) marketed overseas</td>
<td>NA</td>
</tr>
<tr>
<td>5.2</td>
<td>Application for the domestic marketing authorization of non-original drugs (both API and DP) marketed overseas</td>
<td>NA</td>
</tr>
</tbody>
</table>

- No defined time point of qualifying New Drugs at CTA or NDA?
- Cat 5 of the originators
  - Lack of Regulatory data protection
  - Unclear impact on MA related policies about Cat. 5

Note:
*Original drugs*: the drugs marketed at home and abroad, owing complete and full data about safety and efficacy to get authorization.

---

- Undefined cut-off date of NDD
- Need to define the tech. requirement clearly
- Unclear benefits for MNC’s
Assessment of Priority Review and Approval

Positive:
- Overall, it is a “Phased Regulatory Document” (阶段性注册文件), aiming to resolve the backlog of drug registration applications.
- From the scope of the regulation, it covers both new drugs and Cat. 5 of originators for MNCs.

Unclear Procedures need to seek CFDA’s clarification:
- Mainly including:
  - Unclear expert panel criterion and working procedure
  - Unclear timeframes for each step of the procedure e.g.
    - CDE technical review and supplement review
    - Inspection
  - In NDA phase, it just specified for the local manufactured products. The imported NDAs need to clarify if to be covered.
Challenges to China’s drug innovation

1A Regulation:
- Long and difficult IND process
- Limited regulatory capability and process management
- New drug registration bundled with manufacturing

1B Market access:
- Long tendering process; lack of standards across provinces
- Innovative drugs are not reimbursed in a timely way

1C IPR:
- Lack of patent compensation system
- Patent link system needs further improvement

2 Private capital is unwilling to invest; and there is insufficient support for early research

3 Innovative capability is still weak; platform building is still in its infancy
Fostering a drug innovation ecosystem calls for mindset changes and supportive mechanisms.

**Mindset changes**
- Government roles
- Science-based regulation
- Pro-innovation culture

**Supportive mechanisms**
- Cross-ministry coordination
- Communication platform
- Legislation improvement
Thank You!